Arcutis Biotherapeutics, Inc. logo

Arcutis Biotherapeutics, Inc.

ARQT US

Arcutis Biotherapeutics, Inc.USUnited States Composite

10.25

USD
+0.15
(+1.49%)
-3.78EPS Dil.
-2.71P/E
992.07MMarket Cap
Arcutis Biotherapeutics, Inc.
ARQT:US
(United States Composite)

Recent

price

10.25

P/E

ratio

-2.71

div

yld

- -

ROIC.AI

Business
Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical ZORYVE for the treatment of scalp and body psoriasis and seborrheic dermatitis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; ARQ-255, a topical JAK1 inhibitor for alopecia areata; and ARQ-234, a CD200R fusion protein for the treatment of moderate-to-severe atopic dermatitis. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.

Company News

  • Analysts Are Bullish on These Healthcare Stocks: GoodRx Holdings (GDRX), Arcutis Biotherapeutics (ARQT)

  • Buy Rating on Arcutis Biotherapeutics Bolstered by Projected Q1 Sales Beat and 2024 Upside Potential

  • Are Medical Stocks Lagging AdaptHealth (AHCO) This Year?

  • Sol-Gel’s Collaboration Partner First-to-File ANDA Drug Product Generic to Zoryve® Cream

  • Arcutis to Present at the 23rd Annual Needham Virtual Healthcare Conference

  • Analysts Offer Insights on Healthcare Companies: Marinus (MRNS), Arcutis Biotherapeutics (ARQT) and Axsome Therapeutics (AXSM)

  • Arcutis Biotherapeutics, Inc. (ARQT) Could Find a Support Soon, Here's Why You Should Buy the Stock Now

  • Arcutis Biotherapeutics, Inc. (ARQT) Could Find a Support Soon, Here's Why You Should Buy the Stock Now

  • Is Adverum Biotechnologies (ADVM) Stock Outpacing Its Medical Peers This Year?

  • Wall Street Analysts See a 54.78% Upside in Arcutis Biotherapeutics, Inc. (ARQT): Can the Stock Really Move This High?

  • Wall Street Analysts See a 54.78% Upside in Arcutis Biotherapeutics, Inc. (ARQT): Can the Stock Really Move This High?

  • Arcutis Promotes Todd Tucker to Chief Human Resources Officer

  • Arcutis Presents Late-Breaking Data From INTEGUMENT-PED Phase 3 Trial of Roflumilast Cream 0.05% in Atopic Dermatitis in Children Ages 2 to 5 at the American Academy of Dermatology Annual Meeting

  • New Research Reveals Genomic Profile of Seborrheic Dermatitis and Answers Key Questions on Immune Response and Skin Barrier Dysfunction

  • Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)